Related Experiment Video
Updated: Jul 8, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Empagliflozin Attenuates Liver Inflammation and Fibrosis in NAFLD: Evidence from Mendelian Randomization and Mouse
Chao Fu1, Lijiao Deng1, Xiaochan Zhu1
1Department of Pharmacology, School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, China.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver disorder and a major global health challenge, yet effective pharmacological therapies are lacking. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has shown systemic metabolic and anti-inflammatory benefits, but its liver-specific molecular mechanisms remain incompletely understood. In this study, we evaluated the therapeutic effects of empagliflozin in a diet-induced mouse model of NAFLD, supported by Mendelian randomization analysis. Histological examination, serum biochemistry, and hepatic triglyceride quantification demonstrated that empagliflozin markedly attenuated hepatic steatosis and improved liver injury indices. At the molecular level, empagliflozin suppressed NF-κB-mediated inflammatory signaling and significantly downregulated fibrotic markers including α-SMA and COL1A1, while modulating TIMP-1 and MMP-9 expression. Collectively, these findings reveal that empagliflozin ameliorates NAFLD by inhibiting inflammatory and fibrotic molecular pathways, highlighting its potential as a mechanism-based therapeutic option for NAFLD.
Insights
Empagliflozin effectively treats non-alcoholic fatty liver disease (NAFLD) by reducing liver fat and inflammation. This study shows empagliflozin inhibits key molecular pathways involved in NAFLD progression.
Area of Science:
- Hepatology
- Pharmacology
- Molecular Biology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a widespread liver condition with limited treatment options.
- Empagliflozin, an SGLT2 inhibitor, offers metabolic benefits, but its liver-specific actions are not fully understood.
Purpose of the Study:
- To investigate the therapeutic effects and molecular mechanisms of empagliflozin in a diet-induced mouse model of NAFLD.
- To support findings with Mendelian randomization analysis.
Main Methods:
- Diet-induced mouse model of NAFLD.
- Histological examination and serum biochemistry analysis.
- Hepatic triglyceride quantification and molecular pathway analysis (NF-κB, TIMP-1, MMP-9).
Main Results:
- Empagliflozin significantly reduced hepatic steatosis and improved liver injury markers.
- The drug suppressed NF-κB inflammatory signaling in the liver.
- Empagliflozin downregulated fibrotic markers (α-SMA, COL1A1) and modulated TIMP-1/MMP-9 expression.
Conclusions:
- Empagliflozin ameliorates NAFLD by targeting hepatic inflammatory and fibrotic pathways.
- Empagliflozin demonstrates potential as a mechanism-based therapy for non-alcoholic fatty liver disease.
